LLAI — LungLife AI Income Statement
0.000.00%
Last trade - 00:00- £1.07m
- -£0.71m
- $0.05m
Annual income statement for LungLife AI, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | Interim Report | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.205 | 0.196 | 0.024 | 0.046 |
| Cost of Revenue | ||||
| Gross Profit | 0.017 | 0.099 | 0.024 | 0.046 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 4.27 | 7.22 | 7.76 | 5.68 |
| Operating Profit | -4.06 | -7.02 | -7.74 | -5.63 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -4.84 | -7.43 | -7.6 | -5.41 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -4.84 | -7.44 | -7.61 | -5.41 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -4.84 | -7.44 | -7.61 | -5.41 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -4.84 | -7.44 | -7.61 | -5.41 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.197 | -0.252 | -0.3 | -0.212 |